Edition:
United Kingdom

NanoCarrier Co Ltd (4571.T)

4571.T on Tokyo Stock Exchange

245JPY
16 Aug 2019
Change (% chg)

¥4 (+1.66%)
Prev Close
¥241
Open
¥241
Day's High
¥247
Day's Low
¥240
Volume
574,400
Avg. Vol
1,135,260
52-wk High
¥585
52-wk Low
¥235

Latest Key Developments (Source: Significant Developments)

NanoCarrier starts to discuss business alliance with Ceolia Pharma
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says it starts to discuss business alliance with Ceolia Pharma Co., Ltd., and will cooperate on sale, manufacture and development of pharmaceuticals.  Full Article

NanoCarrier signs license preferential negotiating rights agreement with AccuRna
Monday, 4 Dec 2017 

Dec 4 (Reuters) - NanoCarrier Co Ltd <4571.T> ::Says it and AccuRna Inc entered into a preferential negotiating rights agreement on exclusive right to license of drug development based on co's gene delivery technology.Co will get payment from AccuRna according to the agreement.Co also plans to inject capital into AccuRna Inc .  Full Article

VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Nanocarrier Co Ltd <4571.T>:VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan.Vascular Biogenics Ltd - ‍Nanocarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world​.Vascular - Pursuant to agreement, VBLT to supply nanocarrier with VB-111.Vascular - Nanocarrier will be responsible for all regulatory, other clinical activities necessary for commercialization of VB-111 in Japan.Vascular - VBLT receives up-front payment of $15 million & is entitled to receive greater than $100 million in development & commercial milestone payments​.Vascular Biogenics Ltd - ‍VBLT will also receive tiered royalties on net sales in high-teens​.Vascular Biogenics Ltd - ‍Other terms of agreement not disclosed​.  Full Article

Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan.Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan.Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co.  Full Article